Literature DB >> 12846984

Convergent pathobiologic model of Parkinson's disease.

Kathleen A Maguire-Zeiss1, Howard J Federoff.   

Abstract

The etiology of Parkinson's disease (PD) has yet to be delineated. Human genetic studies as well as neurotoxicant and transgenic animal models of PD suggest that multiple events trigger the initiation of this progressive age-related neurodegenerative disorder. In addition, we propose that despite disparate disease triggers a convergent pathobiologic pathway exists leading to cell death. The common pathway model posits that both familial and sporadic forms of Parkinson's disease obligately share a common pathophysiological substrate. Herein we discuss the evidence for a common pathway model of Parkinson's disease through a review of synuclein transgenic models and outline an approach for the identification of shared therapeutic targets. We end with a discussion of a potential alternative therapy for Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12846984     DOI: 10.1111/j.1749-6632.2003.tb07473.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  15 in total

Review 1.  Microarrays in Parkinson's disease: a systematic approach.

Authors:  Renee M Miller; Howard J Federoff
Journal:  NeuroRx       Date:  2006-07

2.  Dopamine and paraquat enhance α-synuclein-induced alterations in membrane conductance.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  Neurotox Res       Date:  2011-07-07       Impact factor: 3.911

Review 3.  Environmental toxins and alpha-synuclein in Parkinson's disease.

Authors:  Yanying Liu; Hui Yang
Journal:  Mol Neurobiol       Date:  2005       Impact factor: 5.590

Review 4.  Gene therapy in Parkinson's disease: rationale and current status.

Authors:  Li Rebekah Feng; Kathleen A Maguire-Zeiss
Journal:  CNS Drugs       Date:  2010-03       Impact factor: 5.749

5.  Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology.

Authors:  Filip Simunovic; Ming Yi; Yulei Wang; Laurel Macey; Lauren T Brown; Anna M Krichevsky; Susan L Andersen; Robert M Stephens; Francine M Benes; Kai C Sonntag
Journal:  Brain       Date:  2008-12-03       Impact factor: 13.501

Review 6.  Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.

Authors:  Vladimir N Uversky; David Eliezer
Journal:  Curr Protein Pept Sci       Date:  2009-10       Impact factor: 3.272

Review 7.  alpha-Synuclein: a therapeutic target for Parkinson's disease?

Authors:  Kathleen A Maguire-Zeiss
Journal:  Pharmacol Res       Date:  2008-09-16       Impact factor: 7.658

Review 8.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease.

Authors:  Isaac G Onyango
Journal:  Neurochem Res       Date:  2007-10-17       Impact factor: 3.996

Review 9.  Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases.

Authors:  Kathleen A Maguire-Zeiss; Howard J Federoff
Journal:  J Neuroimmune Pharmacol       Date:  2008-10-18       Impact factor: 4.147

10.  Synuclein activates microglia in a model of Parkinson's disease.

Authors:  Xiaomin Su; Kathleen A Maguire-Zeiss; Rita Giuliano; Landa Prifti; Karthik Venkatesh; Howard J Federoff
Journal:  Neurobiol Aging       Date:  2007-05-29       Impact factor: 4.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.